Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s key programs and upcoming catalysts as it enters what management expects to be a pivotal year. Leire discussed why 2026 is shaping up as “a year of catalysts” for the company, with particular focus on the dog ageing trial, progress in MASH, and the group’s approach to partnerships and licensing. Leire explained that the dog longevity study is the nearest catalyst, with the trial expected to be unblinded shortly and early efficacy readouts anticipated in the near term. While safety has already been confirmed, the study remains blinded, meaning efficacy results are still unknown. The first data will focus on biological age, measured using a methylation clock, with a more detailed analysis of muscle biopsies and mitochondrial function to follow. According to Leire, “this trial could be very important for our shareholders, because it will trigger a deal with an animal health company bringing non-dilutive money in the company.” The interview also explored Genflow’s repositioning in MASH toward advanced fibrosis and the prevention of hepatocellular carcinoma. Leire highlighted the significant unmet need in late-stage disease, noting that recent therapies target earlier stages and leave patients with advanced fibrosis facing limited options. He said the company’s preclinical data have been encouraging and form a key part of the IND package, helping differentiate Genflow from existing and emerging treatments. In addition, Leire discussed the company’s licensing strategy, including plans to out-license the dog program to an animal health specialist and pursue early-stage partnerships for glaucoma, while retaining focus on age-related conditions such as sarcopenia. With meetings planned during JPMorgan week, Leire said the company is seeking non-dilutive capital and strategic validation as it moves forward. For more interviews like this, visit Proactive’s YouTube channel, give the video a like, subscribe to the channel, and enable notifications so you don’t miss future updates. #GenflowBiosciences #GENF #GENFF #Biotechnology #LongevityResearch #DogAging #AnimalHealth #MASH #LiverDisease #Fibrosis #BiotechStocks #LifeSciences #LicensingDeals #JPmorganHealthcare